Literature DB >> 26508029

Overexpression of OCT4 contributes to progression of hepatocellular carcinoma.

Gang Xu1, Fuzhen Qi1, Jianhuai Zhang1, Jianbo Xu1, Ting Shi1, Yi Miao2.   

Abstract

The abnormal change of octamer transcription factor 4 (OCT4) is associated with tumor progression; however, its effect on hepatocellular carcinoma (HCC) behavior remains unclear. The purpose of this study was to determine the correlation between HCC and OCT4. In the present study, IHC, western blot analysis, and QRT-PCR were performed to identify differentially expressed OCT4 in a series of HCC tissues and adjacent non-cancerous tissues. In addition, the functions of OCT4 on HCC progression were studied in vitro. Silencing of OCT4 with siRNA was performed in HCC cell lines, and the impact on proliferation, migration, and the EMT marker of HCC was analyzed. Our results found that OCT4 levels were significantly higher in HCC tissues compared with the adjacent non-cancerous tissues. Furthermore, OCT4 siRNA significantly reduced the proliferation rate of SMMC-7721 and HepG2 cells, inhibited the migration and inversion, and could reverse EMT in HCC cells, indicating that OCT4 plays a critical role in HCC progression. Our data suggest that the pathogenesis of human HCC may be mediated by OCT4, and thus, OCT4 could represent selective targets for the molecularly targeted treatments of HCC.

Entities:  

Keywords:  Epithelial-to-mesenchymal transition; Hepatocellular carcinoma; Migration; Octamer transcription factor 4; Proliferation

Mesh:

Substances:

Year:  2015        PMID: 26508029     DOI: 10.1007/s13277-015-4285-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  21 in total

Review 1.  Treatment of hepatocellular carcinoma: a systematic review.

Authors:  Shibo Lin; Katrin Hoffmann; Peter Schemmer
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

2.  OCT4B1, a novel spliced variant of OCT4, is highly expressed in gastric cancer and acts as an antiapoptotic factor.

Authors:  Malek H Asadi; Seyed J Mowla; Fardin Fathi; Ahmad Aleyasin; Jamshid Asadzadeh; Yaser Atlasi
Journal:  Int J Cancer       Date:  2010-11-03       Impact factor: 7.396

3.  Oct4 is expressed in human gliomas and promotes colony formation in glioma cells.

Authors:  Zhanhui Du; Deyong Jia; Shangming Liu; Fuwu Wang; Gang Li; Yanmin Zhang; Xinmin Cao; Eng-Ang Ling; Aijun Hao
Journal:  Glia       Date:  2009-05       Impact factor: 7.452

4.  Circulating tumor cells measurements in hepatocellular carcinoma.

Authors:  Franck Chiappini
Journal:  Int J Hepatol       Date:  2012-05-28

5.  Downregulation of microRNA-100 enhances the ICMT-Rac1 signaling and promotes metastasis of hepatocellular carcinoma cells.

Authors:  Hui-Chao Zhou; Jian-Hong Fang; Xu Luo; Lei Zhang; Jine Yang; Chong Zhang; Shi-Mei Zhuang
Journal:  Oncotarget       Date:  2014-12-15

Review 6.  Treatment for hepatocellular carcinoma in elderly patients: a literature review.

Authors:  Hiroki Nishikawa; Toru Kimura; Ryuichi Kita; Yukio Osaki
Journal:  J Cancer       Date:  2013-09-14       Impact factor: 4.207

7.  Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma.

Authors:  Catia Giovannini; Manuela Minguzzi; Michele Baglioni; Francesca Fornari; Ferdinando Giannone; Matteo Ravaioli; Matteo Cescon; Pasquale Chieco; Luigi Bolondi; Laura Gramantieri
Journal:  Oncotarget       Date:  2014-11-15

8.  Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma.

Authors:  Xiaodong He; Jingjing Li; Weidong Guo; Wei Liu; Jia Yu; Wei Song; Lei Dong; Fang Wang; Shuangni Yu; Yi Zheng; Songsen Chen; Yan Kong; Changzheng Liu
Journal:  Oncotarget       Date:  2015-02-10

9.  The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis.

Authors:  Yoshiki Murakami; Akihiro Tamori; Saori Itami; Toshihito Tanahashi; Hidenori Toyoda; Masami Tanaka; Weihong Wu; Nariso Brojigin; Yuji Kaneoka; Atsuyuki Maeda; Takashi Kumada; Norifumi Kawada; Shoji Kubo; Masahiko Kuroda
Journal:  BMC Cancer       Date:  2013-03-04       Impact factor: 4.430

10.  Autochthonous mouse melanoma and mammary tumors do not express the pluripotency genes Oct4 and Nanog.

Authors:  Caroline Schreiber; Vanessa Kuch; Viktor Umansky; Jonathan P Sleeman
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

View more
  6 in total

1.  Overexpression of SMC4 predicts a poor prognosis in cervical cancer and facilitates cancer cell malignancy phenotype by activating NF-κB pathway.

Authors:  Hui He; Cui Zheng; Yunxian Tang
Journal:  Hum Cell       Date:  2021-09-03       Impact factor: 4.174

2.  Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance.

Authors:  Jae Moon Gwak; Milim Kim; Hyun Jeong Kim; Min Hye Jang; So Yeon Park
Journal:  Oncotarget       Date:  2017-05-30

3.  OCT4, SOX2, and NANOG positive expression correlates with poor differentiation, advanced disease stages, and worse overall survival in HER2+ breast cancer patients.

Authors:  Fan Yang; Jiaming Zhang; Hua Yang
Journal:  Onco Targets Ther       Date:  2018-11-06       Impact factor: 4.147

4.  Clinical significance of cytokeratin 19 and OCT4 as survival markers in non-metastatic and metastatic breast cancer patients.

Authors:  Lobna A Abdelaziz; Huda F Ebian; Ola A Harb; Yousef Nosery; Heba F Taha; Nashwa Nawar
Journal:  Contemp Oncol (Pozn)       Date:  2022-03-30

5.  Increased Expression of SETD7 Promotes Cell Proliferation by Regulating Cell Cycle and Indicates Poor Prognosis in Hepatocellular Carcinoma.

Authors:  Yuanyuan Chen; Shengsheng Yang; Jiewei Hu; Chaoqin Yu; Miaoxia He; Zailong Cai
Journal:  PLoS One       Date:  2016-05-16       Impact factor: 3.240

6.  Human papillomavirus E7 binds Oct4 and regulates its activity in HPV-associated cervical cancers.

Authors:  Theofano Panayiotou; Stella Michael; Apostolos Zaravinos; Ece Demirag; Charis Achilleos; Katerina Strati
Journal:  PLoS Pathog       Date:  2020-04-16       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.